Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
| العنوان: | Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today? |
|---|---|
| المؤلفون: | Umberto Malapelle, Alfredo Addeo, Alex Friedlaender, Giuseppe Luigi Banna, Pasquale Pisapia |
| المساهمون: | Friedlaender, A., Banna, G., Malapelle, U., Pisapia, P., Addeo, A. |
| المصدر: | Frontiers in Oncology, Vol 9 (2019) Frontiers in Oncology |
| بيانات النشر: | Frontiers Media SA, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, Mini Review, medicine.medical_treatment, Cell, Population, squamous cell lung cancer (SQCLC), lcsh:RC254-282, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, medicine, Lung cancer, education, targeted therapy (TT), non-small cell lung cancer, education.field_of_study, genetic alterations, Lung, business.industry, NGS—next generation sequencing, FGFR1 amplification, Immunotherapy, PI3 K, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Precision medicine, respiratory tract diseases, Genetic alteration, 030104 developmental biology, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, MET, Cancer research, Adenocarcinoma, business, NGS-next generation sequencing |
| الوصف: | Lung cancer is the leading cause of cancer-related mortality and will affect ∼6% of the population. It is divided into two broad categories, small cell lung cancer and non-small cell lung cancer (NSCLC), the latter representing 85% of all lung cancers. It mainly comprises adenocarcinoma (65%) and squamous cell carcinoma (30%) histologies. In recent years, there have been two major therapeutic advances in NSCLC. The first, immunotherapy, has greatly improved the prognosis of adenocarcinomas and squamous cell carcinomas. The second, the treatment of targetable driver mutations, has so far only benefited adenocarcinomas. Squamous cell carcinoma carries a high rate of mutations and is found mostly among smokers. This raises two important problems: identifying driver mutations and finding those of clinical relevance. Large-scale genomic analyses such as The Cancer Genome Atlas have allowed for the identification of frequent gene alterations, although their role and potential for targeted therapy remain unknown. The emergence of next generation sequencing has changed the landscape of precision medicine, in particular in lung cancer. In this review, we discuss the landscape of genetic alterations found in squamous cell lung cancer, the results of current targeted therapy trials, the difficulties in identifying and treating these alterations and how to integrate modern tools in clinical practice. |
| تدمد: | 2234-943X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69150dd5acf82ec47cca75877f2863efTest https://doi.org/10.3389/fonc.2019.00166Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....69150dd5acf82ec47cca75877f2863ef |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2234943X |
|---|